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HDAC6 inhibitors sensitize 
non‑mesenchymal triple‑negative 
breast cancer cells to cysteine 
deprivation
Tahiyat Alothaim, Morgan Charbonneau & Xiaohu Tang*
Triple‑negative breast cancer (TNBC) is a highly malignant type of breast cancer and lacks effective 
therapy. Targeting cysteine‑dependence is an emerging strategy to treat the mesenchymal TNBC. 
However, many TNBC cells are non‑mesenchymal and unresponsive to cysteine deprivation. To 
overcome such resistance, three selective HDAC6 inhibitors (Tubacin, CAY10603, and Tubastatin 
A), identified by epigenetic compound library screening, can synergize with cysteine deprivation to 
induce cell death in the non‑mesenchymal TNBC. Despite the efficacy of HDAC6 inhibitor, knockout of 
HDAC6 did not mimic the synthetic lethality induced by its inhibitors, indicating that HDAC6 is not the 
actual target of HDAC6 inhibitor in this context. Instead, transcriptomic profiling showed that tubacin 
triggers an extensive gene transcriptional program in combination with erastin, a cysteine transport 
blocker. Notably, the zinc‑related gene response along with an increase of labile zinc was induced 
in cells by the combination treatment. The disturbance of zinc homeostasis was driven by PKCγ 
activation, which revealed that the PKCγ signaling pathway is required for HDAC6 inhibitor‑mediated 
synthetic lethality. Overall, our study identifies a novel function of HDAC6 inhibitors that function as 
potent sensitizers of cysteine deprivation and are capable of abolishing cysteine‑independence in non‑
mesenchymal TNBC.
Triple-negative breast cancer (TNBC) accounts for 15–20% of overall breast cancer cases and exhibits earlier 
age of onset, high metastasis, and aggressiveness with poor clinical outcomes shown by higher relapse and lower 
survival rates than other types of breast  cancer1–3. TNBC contributes to the majority of mortalities of breast 
cancer  patients4–6. Treatments of TNBC patients are still limited to surgery, chemotherapy, or radiation since the 
absence of cell surface receptors makes targeted hormonal therapies impossible. About 50% of TNBC patients 
respond to conventional therapies, but the efficiency of treatments is further limited by tumor metastasis and 
drug  resistance7–11. Therefore, there is an urgent need to develop novel targeted therapies to improve TNBC 
outcomes and reduce patient mortality.
With omics technologies, scientists have gained a deeper understanding of the molecular complexity of 
 cancer1,12,13. Metabolic deregulation is one of the emergent hallmarks in many  cancers14,15. Cellular metabolic 
rewiring often occurs with oncogenic alterations and microenvironmental adaptations to meet the demands of 
tumor cell survival, proliferation, and  invasion16–18. Therefore, targeting metabolic vulnerabilities is a promising 
targeted strategy to treat these cancers. One classical example is that tumor cells acquire glycolysis (the War-
burg effect) even under sufficient supply of oxygen. These tumors become addicted to glucose and are sensitive 
to inhibition of glycolysis by glucose  analogues19,20. Similarly, alterations of amino acid metabolism are often 
observed in many cancers associated with genetic aberrations. For example, glutaminolysis is activated in MYC 
overexpressed tumors to feed the demands of lipids for fast proliferation, and thus MYC-induced tumors typi-
cally need extra  glutamine21,22.
Cysteine dependence/addiction is a common metabolic vulnerability in many types of  cancer23–26. Cysteine 
in cells, mostly derived from extracellular disulfide cystine, is involved in cellular glutathione (GSH) synthesis 
that removes cytotoxic reactive oxygen and nitrogen species (ROS and RNS) via the action of glutathione per-
oxidases (GPXs)27. Cysteine deprivation or inhibition of cystine/glutamate antiporter (the system xC-) by erastin 
or sulfasalazine can limit the GSH synthesis, subsequently accumulate lipid peroxidative stress in cells and ulti-
mately induce ferroptosis in cysteine-dependent tumor  cells23. Alternativity, application of “cysteinase” in vivo 
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has been shown to be a safe approach to suppress tumor growth in mice with effective  efficacy28,29. Therefore, 
targeting cysteine-dependence could be an effective targeted cancer therapy, especially because limiting a single 
amino acid is a relatively feasible method for in vivo  application30,31. Cysteine dependence is a striking feature 
of mesenchymal  TNBC26. However, many TNBC and luminal breast tumor cells are cysteine-independent and 
not effectively responsive to depletion of cysteine. Little is known about the mechanisms that dictate the demand 
of cysteine in TNBC.
Epigenetic alterations are important factors that regulate cancer development and contribute therapeutic 
drug resistance in  cancer32,33. In breast cancer, distinct DNA methylation patterns are observed in luminal and 
basal cancer subtypes when analyzing the omics of 802 breast tumor cases. High DNA methylation and histone 
methylation were found in aggressive metastatic breast  cancer34–37. Such epigenetic differences probably con-
figure various subtypes of breast cancer and dictate cysteine dependence. Therefore, manipulation of epigenetic 
states in cysteine-independent cancer cells could change cysteine-dependence and overcome drug resistance.
By epigenetic compound library screening, we identified HDAC6 inhibitors as potent sensitizers that confer 
cysteine-dependence in non-mesenchymal TNBC. We showed that HDAC6 inhibitors induce the synthetic 
lethality of cysteine deprivation. This event occurs via an HDAC6-independent manner and requires activation 
of PKCγ signaling pathway. Our study suggested that HDAC6 inhibitors can be used as therapeutic adjuvants 
of cysteine deprivation to treat various non-mesenchymal breast cancers.
Results
HDAC6 inhibitors sensitize non‑mesenchymal TNBC to cysteine deprivation. Cysteine-
dependence is a novel feature in mesenchymal TNBC cells. However, we found that ~ 50% of TNBCs are non-
mesenchymal, and enriched expression of epithelial genes (Fig. S1A–C). These non-mesenchymal TNBC cells, 
such as HCC70 and HCC38, were cysteine-independent and resistant to erastin, a blocker of cysteine trans-
port (Fig. S1D), distinct from mesenchymal HBL100 and MDA-MB-231 cells. To overcome such resistances in 
non-mesenchymal tumor cells and identify potential sensitizers, three inhibitors of the histone deacetylase 6 
(HDAC6)—Tubacin, CAY10603, and Tubastatin A were identified by the epigenetic compound library screen-
ing, which dramatically induce synthetic-lethal death under the cysteine-depleted condition (Fig. 1A,B). We 
further confirmed that tubacin induced synthetic-lethal cell death in non-mesenchymal MDA-MB-436 and 
HCC70 cells when cotreated with either cysteine deprivation or erastin; Either tubucin or erastin alone had 
no significant cytotoxic effect (Fig. 1C,D and Fig. S2A,B). The effectiveness of combined application of tubacin 
Figure 1.  Epigenetic compound library screening identifies HDAC6 inhibitors to promote cell death of 
cystine deprivation. (A,B) Relative cell survival of TNBC HCC38 and luminal T47D cells treated with 
epigenetic compounds under cystine-depleted (-Cys) and cystine-replete (+ Cys) conditions were determined 
by CellTiter-Glo assay at 72 h. (C,D) Cell viability of TNBC MDA-MB-436 cells was measured by ATP level 
(C; n = 3; *p < 0.01) or stained by crystal violet (D) under either cystine-replete (Con), cystine-depleted (-Cys), 
5 μM tubacin (T), or 5 μM tubacin under cystine-depleted (-Cys + T) treatments for 72 h. (E,F) Survival 
rate of HCC38, HCC70, and T47D cells in response to either control (Con), 5 μM erastin, 5 μM tubacin, 
or combination of erastin and tubacin (E + T) were determined by trypan blue counting (E; **p < 0.001) or 
CellTiter-Glo assay (F; n = 3; #p < 0.001). (G) Cell viability of HCC38 cells was measured by CellTiter-Glo assay 
under either control (Con), 5 μM erastin, various concentrations of Cay10603 (Cay) 0.5, 1, and 2 μM, or erastin 
plus Cay (E + Cay) treatments for 48 h (n = 3; ##p < 0.005). (H) Relative cell survival of HCC38 was assessed by 
crystal violet staining after treatment with Con, 5 μM erastin, 2 μM Cay, or E + Cay for 48 h.
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plus erastin was further observed in other tumor subtypes, including luminal and HER-2 positive tumor cells 
(Fig. 1E,F and Fig. S2C). Similarly, CAY10603 significantly promoted the lethal effects of erastin in non-mes-
enchymal TNBC as well (Fig. 1G,H and Fig. S2D). Colony formation assay further confirmed that tubacin plus 
erastin siginificantly suppressed long-term tumor cell growth in comparison with individual drug treatmnet 
(Fig. S2E). However, the synergistic effect of tubacin and erastin was not evident in MCF10A, a non-cancerous 
cells (Fig. S2F). Taken together, our epigenetic drug screening identified HDAC6 inhibitors as potent sensitizers 
capable of promoting synthetic lethality of cysteine depletion in non-mesenchymal tumor cells.
HDAC6 inhibitors synergize with erastin to induce a mixed cell death. To characterize the death 
pathway induced by the combination application of erastin and HDAC6 inhibitor, we examined various death 
and signaling markers, and evaluated the protective effect of different types of cell death inhibitors. Erastin plus 
tubacin treatment caused significant activation of p38 death signaling, increases of DNA double-strand breaks as 
indicated by phosphorylation of H2AX, and partial cleavages of PARP1 and caspase-3 (Fig. 2A,B), while either 
erastin or tubacin individually failed to activate such death signaling and markers. As the substrate of HDAC6, 
α-tubulin was strongly acetylated by tubacin. Both necroptosis inhibitor Necrostatin-1 and ferroptosis inhibitor 
Ferrostatin-1 fully rescued cells from death induced by erastin plus tubacin, while the pan-caspase inhibitor 
Q-Vad had partial protective effects (Fig. 2C–E). Similarly, the lethal effects promoted by CAY10603 were pre-
vented by different types of cell death inhibitors (Fig. 2F). This data suggested that HDAC6 inhibitors synergize 
with erastin to activate a mixed cell death program in non-mesenchymal TNBC.
HDAC6 is not required for the tubacin‑mediated synthetic lethality.. Next, we examined whether 
repression of HDAC6 expression mimics the lethal-promoting effect of tubacin. Unexpectedly, silencing of 
HDAC6 gene expression by different shRNAs did not promote cell death in the presence of erastin, although the 
protein level of HDAC6 was reduced and the acetylation level of tubulin was significantly increased (Fig. S3A–
C). We hypothesized that shRNA might be unable to sufficiently suppress endogenous HDAC6 to mimic the 
potency of tubacin. To that end, we employed CRISPR/Cas9 gene editing to knockout HDAC6 in TNBC HCC38 
Figure 2.  HDAC6 inhibitors synergize with erastin to induce a mixed type of cell death. (A,B) Immunoblot 
analysis of acetylated-tubulin, PARP1, cleaved Caspase-3, phosphorylated p38, and H2AX protein expression in 
HCC38 cells (A; 24 h) and in MDA-MB-436 cells (B; 36 h) under either control (Con), 5 μM erastin (E), 5 μM 
tubacin (T), or combination of erastin and tubacin (E + T) treatments; β-Actin serves as a protein normalization 
control. (C, D) Relative cell survival of HCC38 (48 h) and MDA-MB-436 (72 h) were measured by CellTiter-Glo 
assay (C; n = 3; *p < 0.001) or assessed by crystal violet staining in HCC38 (D) under either Con, combination 
of E + T, or E + T with different cell death inhibitors Q-Vad (10 μM), Fer-1(10 μM), Nec-1 (20 μM) treatments 
for 48 h. (E) Immunoblot analysis of indicated protein expression in HCC38 cells treated as (C) for 24 h. (F) 
Relative cell survival of HCC38 cells under either control (Con), combination of erastin and 2 μM Cay (E + Cay), 
or E + Cay with following death inhibitors Q-Vad 10 μM, Fer-1 (10 μM; **p < 0.005), Nec-1 (20 μM; **p < 0.005) 
treatments for 48 h.
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and MDA-MB-436 cells, and luminal T47D cells. Independent HDAC6-null cell clones were isolated based 
on deletion of HDAC6 protein expression and acetylation of tubulin (Fig.  3A–C upper panel). Surprisingly, 
knockout of HDAC6 also did not promote the synthetic-lethal response with erastin as shown by no significant 
ATP decrease and cell loss in HDAC6-null cell clones (Fig. 3A–C lower panel and 3E). However, erastin plus 
tubacin together induced similar cell death (Fig. 3A–C lower panel and 3E) and death markers (Fig. 3D) in either 
HDAC6-null or HDAC6 intact cells, despite the HDAC6 status. Taken together, our data provided evidence that 
the lethal-promoting effect of HDAC6 inhibitors is independent of endogenous HDAC6, which revealed the 
possibility of a new off-target molecule. The sphingolipid biosynthesis was previously identified as a so-called 
off-target of  tubacin38. However, myriocin, an inhibitor of sphingolipid synthesis, failed to promote cell death in 
the presence of erastin in non-mesenchymal tumor cells (Fig. S3D,E).
Tubacin synergizes with erastin to activate a lethal gene transcriptional program. Microarray 
transcriptional profiling analysis was employed to identify the molecular mechanism of tubacin. By the super-
vised cluster analysis, either erastin or tubucin individually induced mild or few changes in gene expression. 
However, tubacin plus erastin dramatically induced or repressed expression of large groups of genes (Fig. 4A), 
such as apoptotic genes (Bim, BNIP3, and Puma) and genes involved in endoplasmic reticulum and oxidative 
stress (ATF3, CHOP, and HOMX1). GSEA revealed that the gene responses activated by erastin plus tubacin are 
similar to gene changes induced by photodynamic therapy (PDT) (Fig. 4B), which is a well-established cancer 
Figure 3.  Knockout of HDAC6 fails to mimic tubacin to induce synergistic cell death. (A–C) Immunoblotting 
analysis (Upper panel) of HDAC6 and acetylated tubulin in the empty vector (Vec) cells and sgRNA HDAC6 
(gHDAC6) clones of HCC38 (A), MDA-MB-436 (B), and T47D (C) cells. Relative cell survival (Lower panel) 
was measured by the ATP level in indicated cells under either control (Con), 5 μM erastin, or combination 
of erastin and 5 μM tubacin (E + T) treatment for 72 h (n = 3). (D) Western blot analysis of indicted protein 
expression in HCC38 Vec or gHDAC6 HCC38 cells (Clone #1) under either control (Con), 5 μM erastin (E), 5 
μM tubacin (T), or combination of erastin and tubacin (E + T) treatments for 24 h. (E) Cell viability was assessed 
by crystal violet staining in MDA-MB-436 Vec or gHDAC6 clones under either control (Con), erastin (E), or 
erastin plus different doses of tubacin (E + T) treatments for 72 h.
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therapy to cause tumor  ablation39. RT-qPCR and immunoblotting data confirmed that apoptotic genes were 
strongly induced by the combination treatment, but not by either erastin or tubacin alone (Fig. 4C,D). Gene 
changes induced by erastin plus tubacin were similar in HDAC6-null cells in comparison with HDAC6 wild 
type cells (Fig. 4E,F). Taken together, the lethal gene response of tubacin plus erastin reiterated the potential of 
tubacin to confer cysteine-dependence in non-mesenchymal TNBC via an HDAC6-independent manner.
Tubacin synergizes with erastin to induce cellular zinc response. Ferroptosis is an iron-dependent 
cell death that is able to be induced by erastin. In our gene expression profiling, gene changes involved in iron 
metabolism were not observed. Interestingly, the genes involved in zinc transport, ZnT1 and ZnT2, as well as 
the genes related to zinc storage, metallothioneins MT1G/1H/1 M, were highly induced by erastin plus tubacin 
(Fig. 4A). RT-qPCR confirmed that these zinc-related genes were strongly induced by erastin plus tubacin, but 
not by either erastin or tubacin alone (Fig. 5A,B). Similarly, CAY10603 in combination with erastin strongly 
activated the zinc-related gene response (Fig. 5C). Zinc is known to cause ROS production and induce a mixed 
type of cell death, including apoptosis and  necrosis40,41. Therefore, we examined whether the level of zinc is 
altered by erastin plus tubacin. Indeed, FluoZin™-3, a  Zn2+-selective indicator, detected that the level of labile 
zinc was highly increased in cells by erastin and tubacin, but not significantly by either erastin or tubacin alone 
(Fig. 5D and Fig. S4A). Labile zinc mostly accumulated in the nucleus, as it co-localized with nuclear DNA. The 
total cellular amount of zinc measured by ICP-OES, including both labile and bound zinc, was not significantly 
altered under any treatments (Fig. 5E), indicating that the labile zinc originated from zinc cellular proteins or 
compartments; it was not imported from culture media. However, chelation of labile zinc with  TPEN42 did not 
protect cells from cell death induced by erastin plus tubacin (Fig. 5F and Fig. S4B), indicating that labile zinc is 
not the causative agent of cell death.
Inhibition of PKC suppresses the synthetic lethality of tubacin. Considering that zinc functions as 
a structural or modulatory component of many regulatory and signaling  proteins43,44, the increase of labile zinc 
in cells is probably an indication of cellular protein function or signaling alterations. Particularly, zinc release 
from protein kinase C (PKC) is a common event during PKC activation by reactive oxygen species (ROS) during 
cell  death45,46. Therefore, we examined the role of PKC in the synthetic lethality of tubacin. We found that Gö 
6983, a PKC inhibitor with a broad inhibitory  spectrum47, rescued cells from cell death induced by erastin and 
tubacin, while Gö 6976, a selective inhibitor of PKC α/β , had no protective role (Fig. 6A and Fig. S5A). Immu-
noblotting and RT-qPCR analysis confirmed that Gö 6983 abolished phosphorylation of PKC substrates and the 
induction of cell death genes induced by erastin plus tubacin (Fig. 6B,C and Fig. S5B). Moreover, Gö 6983 sig-
Figure 4.  Tubacin synergizes with erastin to induce an extensive gene transcriptional response. (A) Heatmap 
cluster view of transcriptional profiling in HCC38 cells under treatments of either control (Con), 5 μM erastin 
(E), 5 μM tubacin (T), or combination of erastin and tubacin (E + T) for 24 h. (B) Gene enrichment of GSEA 
analysis in the gene expression profile induced by E + T. (C) RT-qPCR analysis of apoptotic gene expression in 
HCC38 and MDA-MB-436 (n = 3; *p < 0.001) cells treated as (A). (D) Immunoblot analysis of BCL-2 and BNIP3 
protein expression in HCC38 cells. (E) RT-qPCR analysis of apoptotic gene expression (#p < 0.0001) in HCC38 
Vector and gHDAC6 #1 cells treated as (A). (F) Immunoblot analysis of BNIP3 protein expression in HCC38 
Vec and gHDAC6 #1 cells.
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nificantly suppressed the zinc-related gene response and decreased labile zinc in cells (Fig. 6D,E and Fig. S5C). 
These results suggested that activation of PKC, but not PKC α/β , is required for the tubacin-mediated cell death.
PKCγ is required for the tubacin‑mediated synthetic lethality. To examine which member of PKC 
family is required for the synthetic lethality of tubacin, two additional PKC inhibitors, bisindolylmaleimide I and 
sotrastaurin, with slightly different inhibitory spectrums were used. Similar to Gö 6983, bisindolylmaleimide I 
strongly protected cells from cell death induced by erastin plus tubacin, but sotrastaurin did not (Fig. 7A,B). 
Based on the protective role and inhibitory spectrums of various PKC inhibitors, PKCγ stood out as the can-
didate kinase since it is inhibited by Gö 6983 and bisindolylmaleimide I, but not by Gö 6976 and sotrastaurin. 
Additionally, PKCγ was transiently phosphorylated in the early phase and associated with the phosphorylation 
of PKC substrates during the erastin plus tubacin treatment. On the other hand, the phosphorylation of PKC δ/θ 
occurred in the later phase (Fig. 7C). Knockdown of PKCγ by shPKCγ significantly alleviated cell death induced 
by erastin plus tubacin in non-mesenchymal TNBC cells (Fig. 7D,F and Fig. S6A). Consistent with the protec-
tive role of PKCγ, its knockdown suppressed induction of cell death markers (PARP1, pho-H2AX, and BNIP3) 
(Fig. 7E and Fig. S6A,B). Taken together, activation of PKCγ is required for the synthetic lethality of tubacin.
Discussion
TNBC is the most challenging subtype of breast cancer and overall its survival rate is  low48. Developing novel and 
precise targeted therapies is urgently needed. Targeting cancer metabolism emerges as a promising strategy to 
treat some cancers with metabolic deregulations. Particularly, cysteine depletion can eradicate a subset of TNBC 
with highly mesenchymal states (EMT)49. However, many TNBCs with epithelial features, as well as luminal 
breast cancers are cysteine-independent and unresponsive to cysteine deprivation. Epigenetic alterations can 
change tumor identity, metabolism, heterogeneity, and result in drug resistances in  cancer35,37. Many epigenetic 
activators or inhibitors are employed as therapeutic adjuvants to enhance chemotherapy efficacy and overcome 
Figure 5.  The zinc-related gene response is triggered by erastin plus tubacin. (A,B) RT-qPCR analysis of 
zinc-related gene expression (n = 3; *p < 0.005) in HCC38 cells (A; 24 h) and MDA-MB-436 (B; 36 h) under 
treatments of either control (Con), 5 μM erastin (E), 5 μM tubacin (T), or erastin plus tubacin (E + T). (C) 
RT-qPCR analysis of zinc-related gene expression (n = 3; **p < 0.005) in MDA-MB-436 (36 h) under treatments 
of either control (Con), 5 μM erastin (E), 5 μM Cay10603 (Cay), or erastin plus Cay10603 (E + Cay). (D) Live 
cell imaging of HCC38 cells that were treated as (A) for 18 h and stained by Fluozin-3 and DAPI (Hoechst 
33342). The size of the scale bar is 100 μm. (E) Total cellular zinc was measured by ICP-AES analysis (n = 3; n.s., 
not significant) in MDA-MB-436 cells under either control (Con), 5 μM erastin (E), 5 μM tubacin (T), or erastin 
plus tubacin (E + T) treatments for 24 h. (F) Relative cell viability of HCC38 cells under either control or E + T 
with different concentrations of TPEN for 48 h (n = 3; n.s., not significant).
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drug  resistance32,33. In line with these ideas, we identified that HDAC6 inhibitors sensitize non-mesenchymal 
TNBC cells and some luminal cancer cells to cysteine deprivation.
HDAC6 is a unique member of the HDAC family that can regulate cell proliferation, metastasis, and inva-
sion in tumors, and can also drive tumor progression and confer drug resistance in some  cancers50–53. Although 
HDAC6 is likely a reasonable molecular target in our context, we have shown that knockout of HDAC6 protein 
expression does not mimic the effects of HDAC6 inhibitors; endogenous HDAC6 removal does not synergize 
with erastin to induce cell death in the non-mesenchymal TNBC. These suggest that the synergistic effect of 
HDAC6 inhibitors occurs via a new cellular molecule or pathway that is entirely independent of HDAC6. We 
aim in future studies to identify such genes or pathways as they can be valuable direct targets to be exploited in 
combination with cysteine deprivation for cancer treatment.
Although the intrinsic target of HDAC6 inhibitors in this study remains unknown, we found that tubacin 
plus erastin triggered many stress and apoptotic gene responses, one of which mimics the gene response of pho-
todynamic therapy (PDT)39. The synthetic lethality of tubacin exhibited as a mixed type of cell death, including 
apoptosis, necroptosis, and ferroptosis. Ferroptosis is an iron-dependent cell death driven by lipid peroxidation 
with necrotic  features54–56. Our transcriptional profiling data didn’t show any iron-related gene response; instead, 
the expression of several zinc-related genes and the increase of labile zinc was prominently induced by erastin 
plus tubacin.
Zinc is a trace but essential metal micronutrient and is integral to many enzymes and regulatory proteins, 
and functions as a signaling messenger in  cells57,58. Although cellular zinc homeostasis is disturbed by tubacin 
plus erastin, we observed that the total amount of zinc, including labile and bound forms, was not significantly 
changed in treated cells; also, chelation of labile zinc didn’t protect cells from death. These suggested that labile 
zinc is not the direct causative agent for cell death, instead, it is an indicator of intracellular signaling perturba-
tions. It’s known that reactive oxygen species (ROS) can cause zinc releasing from oxidized metallothioneins and 
zinc-fingers of abnormal  proteins59. For example, activation of PKC α/β by ROS can release zinc directly from 
PKC α/β zinc fingers into the  cytoplasm45,46. Indeed, inhibition of PKC abolished the release of labile zinc and 
cell death in our study. Specifically, activation of PKCγ is required for the synthetic lethality of tubacin. As one 
of the conventional PKC isozymes, PKCγ is mainly present in the brain and has rarely been explored in studies 
on  cancer60. Recent studies showed that activation of PKCγ increases the migratory capacity of colon  cancer61,62. 
Our study identified a new role of PKCγ in breast cancer, whereby the PKCγ signaling mediates the synthetic 
lethality of tubacin in non-mesenchymal TNBC cells.
Taken together, many TNBC cells are non-mesenchymal and cysteine-independent. HDAC6 inhibitors identi-
fied in our study, particularly tubacin, can overcome the resistance of cysteine deprivation in non-mesenchymal 
TNBC and promote the synthetic lethality of cysteine deprivation. These inhibitors execute their lethal effects 
independent of their canonical target, the HDAC6 protein. Instead, HDAC6 inhibitors, in synergism with eras-
tin, trigger an extensive gene transcriptional program to induce cell death via the PKCγ signaling. HDAC6 
Figure 6.  Inhibition of PKC suppresses increase of labile zinc and cell death. (A) Relative cell survival of 
HCC38 cells under either control or 5 μM erastin and 5 μM tubacin (E + T) treatments with or without PKC 
inhibitor Gö 6976 or Gö 6983 for 72 h (n = 3; *p < 0.005). (B) Western blot analysis in HCC38 cells that were 
treated as (A) for 24 h. (C,D) RT-qPCR expression analysis of apoptotic genes (C; **p < 0.001) and zinc-related 
genes (D; #p < 0.0001). (E) Living cell imaging of HCC38 cells that were treated as (A) for 18 h and stained by 
Fluozin-3 and DAPI (Hoechst 33342). The size of the scale bar is 50 μm.
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inhibitors will be immensely valuable as adjuvants in the application of targeted cysteine-dependence therapy 
to treat various types of breast cancer.
Methods
Cell culture and reagents. All breast tumor cells and 293 T cells were purchased from ATCC and main-
tained as per standard protocols in an incubator with 95% humidity and 5%  CO2 at 37 °C. Cells were cul-
tured in DMEM with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin–streptomycin. Cysteine 
deficient medium was prepared according to the previous  report63. MCF10A cells were maintained as per a 
standard protocol of ATCC and cultured in MEGM supplemented with MEGM bullet kit. Erastin, selective 
HDAC6 inhibitors tubacin, tubastatin A, and CAY10603, Myriocin, and the metal chelator N, N, N′, N′-tetrakis 
(2-pyridylmethyl) ethylenediamine (TEPN) were obtained from Cayman Chemicals (Ann Arbor, Michigan, 
US); Z-VAD-FMK, necrostatin-1, and ferrostatin-1 were purchased from Calbiochem Research Biochemicals 
(Sigma). The molecular probe FluoZin-3 was purchased from Thermo Fisher Scientific. All antibodies used in 
this study were listed in supplementary table 1.
Epigenetic compound library screening. The epigenetic compound library screening was performed in 
TNBC HCC38 and luminal T47D cancer cells. 140 inhibitors of epigenetic regulators were included in the com-
pound library (Cayman chemical). Briefly, cells were seeded in two sets of 96-well plates under either cysteine-
rich or cysteine depleted conditions. Each epigenetic compound at the final concentration of 2 μM was applied 
to these cells. Cell viability was determined at 72 h using the CellTiter-Glo assay kit (Promega).
Lentiviral cell infection. Viral particles were generated in 293T cells by transfecting lentiviral packaging 
plasmids using Lipofectamine 3000 (ThermoFisher Scientific) and collected from cell media after 48 h. The 
targeted cells were infected for 48 h by indicated viruses and further selected by either puromycin or blasticidin 
(Cayman chemical). The pLentiCRISPR-v2-HDAC6 was purchased from GenScript with the targeting sgRNA 
sequence 5’-CAG TGC TAC AGT CTC GCA C. Independent HDAC6-null cell clones were isolated based on the 
complete deletion of HDAC6 protein expression and increased acetylation of tubulin. All shRNAs targeting 
HDAC6 and PKCγ genes were purchased from Sigma. The pLKO1.0 plasmid was used as a control vector for 
infection.
Figure 7.  PKCγ is required for the tubacin-mediated cell death. (A,B) Relative cell survival of HCC38 (A; 
n = 3; *p < 0.001) and MDA-MB-436 (B; n = 3; *p < 0.005) under either control (Con) or 5 μM erastin plus 5 μM 
tubacin (E + T) treatments with or without PKC inhibitors bisindolylmaleimideI (Bis) or sotrastaurin (Sotr) for 
72 h. (C) Immunoblotting protein analysis in MDA-MB-436 cells under either Con or E + T treatments with or 
without Gö 6983 for indicated times. (D) Cell viability of HCC38 Vec and shPKCγ-#1cells under either Con, or 
erastin (5 μM) plus different doses of tubacin for 48 h (n = 4; **p < 0.01). (E) Immunoblotting protein analysis 
in HCC38 Vec and shPKCγ-#1cells under either Con or erastin plus tubacin for 24 h. (F) Cell viability of 
MDA-MB-436 Vec and shPKCγ-#1 cells under either Con or erastin (5 μM) with different doses of tubacin for 
72 h (n = 4; ##p < 0.01).
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Gene expression profiling and geneset enrichment analysis (GSEA). The gene expression profile 
in HCC38 cells treated with either control, erastin, tubacin, or erastin plus tubacin in triplicate for 24 h was 
analyzed by the GeneChip™ Human Gene 2.1 ST 24-Array Plate (ThermoFisher Scientific). The data were depos-
ited in the GEO database (GSE154425). Probe intensities were normalized by RMA module. Gene expression 
changes in treated HCC38 cells were derived by zero-transformation (Δlog2) against those in the control condi-
tion. Probe sets that varied by twofold in at least 3 samples were selected for hierarchical clustering. The pathway 
enrichment was analyzed by Gene Set Enrichment Analysis (GSEA) module using the G2 annotated-genesets 
with default criteria of 1000 permutations.
RNA extraction and real‑time RT‑PCR. RNA was extracted from cells by RNeasy kit (Invitrogen). Total 
RNA (2 µg) was reverse-transcribed to cDNA and the quantitative PCR was performed using SYBR Green PCR 
master mixture (Applied Biosystems). The relative difference in gene expression was normalized with the Actin 
B gene expression using the ΔΔCT method. All primers in this study were listed in supplementary table 2.
Protein immunoblotting analysis. Proteins were extracted from cells using RIPA extraction and lysis 
buffer (Sigma) with the protease and phosphatase inhibitor cocktail (ThermoFisher Scientific). Protein concen-
trations were determined by BCA protein assay. Equal amounts of protein were loaded for immunoblot analysis. 
Signals were detected by the ECL plus Western blotting detection system (Amersham) and visualized by LAS-
4000 lumino image analyzer.
Cell viability and cytotoxicity. Cell viability was measured by either counting of trypan blue negative 
cells, relative ATP levels using CellTiter-Glo assay kit (Promega), or evaluation by crystal violet staining. Cell 
cytotoxicity was measured as protease release using CytoTox-Fluor cytotoxicity assay kit (Promega).
Clonogenic assay. Cells were seeded at a density of 5 ×  103 cells per well in 12-well plates and incubated 
for two days. Then, the cells were treated with drugs for three days, and replaced with fresh culture medium for 
additional two or three weeks at 37 °C. Finally, colonies were stained with 1% crystal violet at room temperature.
Microscopic imaging. To analyze intracellular zinc levels, 7 ×  103 cells were seeded in the 96-well plate 
under various treatments. At the end, cells were stained by a 2 μM FluoZin-3 molecular probe (ThermoFisher 
Scientific) at 37 °C for 30 min. Dialyzed FBS medium was used to ensure that the medium was zinc-free. Addi-
tionally, cells were also stained by 1 µM of 4′,6-diamidino-2-phenylindole (DAPI) for 5 min. Cells were then 
imaged by ZOE™ Fluorescent Cell Imager microscopy.
Cellular zinc level measurement. Total cellular zinc, including labile and bound zinc, was determined 
by ICP-OES (CHORI Elemental Analysis Facility)64. Briefly, 3 ×  106 HCC38 cells under different treatments were 
collected and fully dissolved in 0.25 mL OmniTrace 70%  HNO3 (EMD Chemicals) by microwave digestion. 
Samples were diluted to 5%  HNO3 with OmniTrace water and analyzed with the use of a Vista Pro ICP-OES 
(Varian Vista Pro). Zinc was measured at the 213-nm wavelength with a detection range between 0.005 and 5 
ppm. All associated reagents and plasticware were certified as trace metal-free or tested for trace metal con-
tamination. Zinc concentrations were normalized by total protein mass. All samples were analyzed in triplicate.
Statistical analyses. The significance of differences between groups was determined using a t test. Statisti-
cal analysis was performed using GraphPad Prism version 8.3.1, GraphPad Software, San Diego, California USA, 
www. graph pad. com. A p-value < 0.05 was considered statistically significant. Data were presented in figures as 
mean ± standard deviation (SD).
Data availability
The datasets generated in the current study are available in the Gene Expression Omnibus (GEO) database 
(https:// www. ncbi. nlm. nih. gov/ geo/).
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